## Consolidated Balance Sheets (In Thousands)

		September 30		
		2021	2020	
Assets				
Current assets:				
Cash and cash equivalents	\$	112,828	\$ 164,627	
Short-term investments		360,464	196,075	
Accounts receivable, net		100,949	73,831	
Current portion of investments limited as to use		1,796	1,567	
Inventories		17,373	17,011	
Prepaid expenses and other current assets		21,297	15,836	
Assets held for sale		9,185	110,995	
Total current assets		623,892	579,942	
Investments limited as to use, less current portion		432,376	592,858	
Net property, plant, and equipment		365,482	264,429	
Operating lease right-of-use assets		11,215	12,980	
Investments		15,000	_	
Other assets		19,400	15,592	
Total assets	\$		\$ 1,465,801	
Liabilities and net assets Current liabilities:		CC 108	10,000	
Accounts payable	\$		\$ 40,008	
Accrued compensation and benefits		35,959	24,084	
Accrued interest		4,013	4,033	
Estimated third-party settlements		11,346	8,139	
Current portion of long-term debt		4,367	1,379	
Current portion of operating lease obligations		2,377	3,336	
Contract liability		46,378	64,180	
Other current liabilities		8,303	8,238	
Liabilities held for sale		1,583	67,372	
Total current liabilities		180,513	220,769	
Long-term debt, less current portion		785,413	791,851	
Operating lease obligations, less current portion		8,964	9,725	
Asset retirement obligations		2,442	2,436	
Other long-term liabilities		63,698	86,299	
Total liabilities		1,041,030	1,111,080	
Net assets:				
Without donor restrictions:				
Controlling interest		401,613	339,802	
Noncontrolling interests in subsidiaries		10,904	8,252	
		412,517	348,054	
With donor restrictions – controlling interest		13,818	6,667	
Total net assets		426,335	354,721	
Total liabilities and net assets	_ \$	1,467,365	\$ 1,465,801	

2112-3940145

See accompanying notes.

# Consolidated Statements of Operations and Changes in Net Assets

(In Thousands)

	Year Ended Se 2021	eptember 30 2020	
Revenues and other support without donor restrictions:			
Patient service revenue	\$ 650,347	\$ 564,075	
Other	91,030	68,034	
Net assets released from restrictions used for operations	1,434	1,704	
Total revenues and other support without donor restrictions	742,811	633,813	
Expenses:			
Salaries and benefits	353,619	321,268	
Supplies	186,580	158,076	
General, administrative, and other	77,352	72,370	
Professional fees and purchased services	70,393	52,891	
Depreciation and amortization	32,847	31,104	
Interest	6,142	11,593	
Total expenses	726,933	647,302	
Income (loss) from operations before income (loss)			
from weather related events	15,878	(13,489)	
Income (loss) from weather related events	713	(2,250)	
Income (loss) from operations	16,591	(15,739)	
Nonoperating gains (losses):			
Change in fair value of interest rate swap agreements	243	163	
Net unrealized gains on trading securities	7,507	625	
Investment income	5,064	2,261	
Loss on extinguishment of debt		(1,303)	
Other, net	(4,139)	(6,881)	
	8,675	(5,135)	
Excess (deficiency) of revenues, other support, and			
gains over expenses and losses	25,266	(20,874)	
Less excess of revenues, other support, and gains over	·	, , ,	
expenses and losses attributable to noncontrolling interests	5,542	3,784	
Excess (deficiency) of revenues, other support, and gains over			
expenses and losses attributable to controlling interest	19,724	(24,658)	

Continued on next page

# Consolidated Statements of Operations and Changes in Net Assets (continued) (In Thousands)

	Year Ended Sep 2021		otember 30 2020	
Net assets without donor restrictions:		2021	2020	
Excess (deficiency) of revenues, other support, and gains				
over expenses and losses attributable to controlling interest	\$	19,724 \$	(24,658)	
Excess of revenues, other support, and gains over	*	,	, , ,	
expenses and losses attributable to noncontrolling interests		5,542	3,784	
Net unrealized gains on other-than-trading securities		815	113	
Pension adjustment		15,016	(5,114)	
Other		(1,913)	(736)	
Increase (decrease) in net assets without donor restrictions				
before discontinued operations		39,184	(26,611)	
Income from discontinued operations		25,279	12,677	
Increase (decrease) in net assets without donor restrictions		64,463	(13,934)	
Net assets with donor restrictions:				
Contributions		8,840	1,711	
Net unrealized gains on other-than-trading securities		418	130	
Net assets released from restrictions		(1,434)	(1,704)	
Other		(673)	130	
Increase in net assets with donor restrictions		7,151	267	
Increase (decrease) in net assets		71,614	(13,667)	
Net assets at beginning of year		354,721	368,388	
Net assets at end of year	\$	426,335 \$	354,721	

See accompanying notes.

2112-3940145 5

### Consolidated Statements of Cash Flows (In Thousands)

	Year Ended Septe	ember 30 2020
Operating activities		
Increase (decrease) in net assets	\$ 71,614 \$	(13,667)
Adjustments to reconcile increase (decrease) in net assets to net cash		
provided by operating activities:		
Restricted contributions received	(8,840)	(1,711)
Gain from disposal of subsidiaries	(396)	_
Depreciation and amortization	32,847	31,104
Change in fair value of interest rate swap agreements	(243)	(163)
Loss on extinguishment of debt	_	1,303
Net unrealized gains on other-than-trading securities	(1,233)	(243)
Net unrealized gains on trading securities	(7,507)	(625)
Pension adjustment	(15,016)	5,114
Distributions to noncontrolling interests	2,890	2,930
(Decrease) increase in other long-term liabilities	(7,342)	4,897
(Decrease) increase in contract liability	(17,802)	64,180
Net increase in components of working capital	2,279	18,402
Net cash provided by operating activities	 51,251	111,521
Investing activities		
Purchase of investments	(952,988)	(1,238,337)
Proceeds from sale of investments	961,363	732,733
Increase in other assets	(1,615)	(1,959)
Proceeds from disposal of subsidiaries	36,843	_
Capital expenditures	 (118,863)	(46,374)
Net cash used in investing activities	(75,260)	(553,937)
Financing activities		
Payments on lines of credit	_	(47,500)
Repayments of long-term debt	(5,616)	(93,015)
Issuance of long-term debt	_	682,046
Distributions to noncontrolling interests	(2,890)	(2,930)
Restricted contributions received	8,840	1,711
Net cash (used in) provided by financing activities	 334	540,312
(Decrease) increase in cash, cash equivalents, restricted cash,		
and restricted cash equivalents	(23,675)	97,896
Cash, cash equivalents, restricted cash, and restricted cash equivalents, beginning of period	172,059	74,163
Cash, cash equivalents, restricted cash, and restricted cash equivalents,	 114,000	77,103
end of period	\$ 148,384 \$	172,059

See accompanying notes.